About Cyclin N-terminal domain-containing protein 1
Cyclin N-terminal domain-containing protein 1 (CNTD1) is a protein
from Homo sapiens identified by UniProt accession
Q8N815, 330 residues long.
MolForge cross-references it against 0 known binders and
113 disease associations.
Target properties
| Protein name | Cyclin N-terminal domain-containing protein 1 |
| UniProt accession | Q8N815 |
| Gene | CNTD1 |
| Organism | Homo sapiens |
| Length | 330 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (113)
Diseases linked to this target (Open Targets).
- BMI-adjusted waist circumference · score 0.19
- azoospermia · score 0.10
- partial chromosome Y deletion · score 0.09
- male infertility with teratozoospermia due to single gene mutation · score 0.08
- spermatogenic failures 50 · score 0.08
- spermatogenic failure 25 · score 0.08
- isochromosomy Yp · score 0.07
- spermatogenic failure, X-linked, 2 · score 0.07
- spermatogenic failure 63 · score 0.07
- spermatogenic failure 61 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N815-F1 | alphafold | PREDICTED | 84.55 | — |
Amino-acid sequence (330 residues)
MDGPMRPRSA SLVDFQFGVV ATETIEDALL HLAQQNEQAV REASGRLGRF REPQIVEFVF LLSEQWCLEK SVSYQAVEIL ERFMVKQAEN ICRQATIQPR DNKRESQNWR ALKQQLVNKF TLRLVSCVQL ASKLSFRNKI ISNITVLNFL QALGYLHTKE ELLESELDVL KSLNFRINLP TPLAYVETLL EVLGYNGCLV PAMRLHATCL TLLDLVYLLH EPIYESLLRA SIENSTPSQL QGEKFTSVKE DFMLLAVGII AASAFIQNHE CWSQVVGHLQ SITGIALASI AEFSYAILTH GVGANTPGRQ QSIPPHLAAR ALKTVASSNT
Explore Cyclin N-terminal domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets